Our top pick for
T2 Biosystems, Inc is a diagnostics & research business based in the US. T2 Biosystems shares (TTOO) are listed on the NASDAQ and all prices are listed in US Dollars. T2 Biosystems employs 118 staff and has a trailing 12-month revenue of around USD$13.4 million.
Since the stock market crash in March caused by coronavirus, T2 Biosystems's share price has had significant positive movement.
Its last market close was USD$1.18, which is 23.73% up on its pre-crash value of USD$0.9 and 402.13% up on the lowest point reached during the March crash when the shares fell as low as USD$0.235.
If you had bought USD$1,000 worth of T2 Biosystems shares at the start of February 2020, those shares would have been worth USD$492.99 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,463.84.
|Latest market close||USD$1.18|
|52-week range||USD$0.235 - USD$1.95|
|50-day moving average||USD$1.3|
|200-day moving average||USD$1.2993|
|Wall St. target price||USD$3.22|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.284|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-13)||N/A|
|1 month (2020-10-20)||N/A|
|3 months (2020-08-20)||N/A|
|6 months (2020-05-20)||N/A|
|1 year (2019-11-20)||N/A|
|2 years (2018-11-20)||N/A|
|3 years (2017-11-20)||N/A|
|5 years (2015-11-20)||N/A|
|Revenue TTM||USD$13.4 million|
|Gross profit TTM||USD$-24,754,000|
|Return on assets TTM||-49.43%|
|Return on equity TTM||0%|
|Market capitalisation||USD$167.9 million|
TTM: trailing 12 months
There are currently 11.1 million T2 Biosystems shares held short by investors – that's known as T2 Biosystems's "short interest". This figure is 16.9% down from 13.4 million last month.
There are a few different ways that this level of interest in shorting T2 Biosystems shares can be evaluated.
T2 Biosystems's "short interest ratio" (SIR) is the quantity of T2 Biosystems shares currently shorted divided by the average quantity of T2 Biosystems shares traded daily (recently around 2.8 million). T2 Biosystems's SIR currently stands at 4.01. In other words for every 100,000 T2 Biosystems shares traded daily on the market, roughly 4010 shares are currently held short.
However T2 Biosystems's short interest can also be evaluated against the total number of T2 Biosystems shares, or, against the total number of tradable T2 Biosystems shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case T2 Biosystems's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 T2 Biosystems shares in existence, roughly 80 shares are currently held short) or 0.079% of the tradable shares (for every 100,000 tradable T2 Biosystems shares, roughly 79 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against T2 Biosystems.
Find out more about how you can short T2 Biosystems stock.
We're not expecting T2 Biosystems to pay a dividend over the next 12 months.
Over the last 12 months, T2 Biosystems's shares have ranged in value from as little as $0.235 up to $1.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while T2 Biosystems's is 0.92. This would suggest that T2 Biosystems's shares are less volatile than average (for this exchange).
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance technology that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida Panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it provides T2Bacteria Panel, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2SARS-CoV-2 Panel, a COVID-19 molecular diagnostic test; and T2Resistance Panel for the early and sensitive detection of carbapenemase-resistance markers. Further, it develops T2Cauris Panel, a multi-drug resistant pathogen; and T2Lyme Panel for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC to develop detection diagnostic test panel that adds one additional bacteria species to the existing T2Bacteria product candidate, as well as for testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.